Labelling Review row-Online

Primary Antibodies
Helicobacter pylori
Clone ULC3R New!
1 mL, 0.1 mL liquid NCL-L-Hpylori P (Enzyme)
Polyclonal
1 mL lyophilized NCL-HPp P (Enzyme)
Helicobacter pylori is a motile, helix–shaped Gram–negative,
microaerophilic, bacterial pathogen which is capable of converting from a
spiral form to a coccoid form to favor its survival. Almost 50 percent of the
world’s population, approaching 100 percent in some countries, are
infected. There are numerous strains of Helicobacter pylori which can be
grouped into two broad families, type I and type II, based on their expression
of the hopQ allele. Type I and type II strains are reported to express VacA
(vacuolating toxin) responsible for vacuolation of gastric epithelial cells and
induction of apoptosis. Type I strains are reported to express CagA protein
which is associated with deregulation of intercellular signalling pathways
and initiation of pathogenesis (virulent strains) and are closely related to
gastric diseases such as peptic ulceration, gastric ulceration, chronic
gastritis, mucosa–associated lymphoid tissue (MALT) lymphoma and
intestine type gastric adenocarcinomas. Type II strains are reported not to
express CagA proteins. HopE is a 31 kD porin protein which is part of a
family of 32 outer membrane proteins present in Helicobacter pylori
bacteria. HopE is highly conserved in Helicobacter pylori strains, but not
among other strains of the Helicobacter genus.
Product Specific Information
Clone ULC3R, unlike polyclonal antibodies to Helicobacter pylori, does not
cross-react with Campylobacter jejuni (a gastric bacterium which causes
infective diarrhoea). Clone ULC3R also exhibits more defined staining of H.
pylori bacteria than NCL-HPp. The antibody clone ULC3R, will be useful to
identify and differentiate patients that need antibiotic eradication of the
bacterium from those patients who are at a higher risk of developing clinical
disease related to H. pylori infection.
Human stomach infected with H. pylori: immunohistochemical staining for H. pylori using
NCL-L-Hpylori. Paraffin section.
/ 118
For detailed information on all products please visit our website:
www.leica-microsystems.com
Hepatitis B virus Antibodies
Clone LF161
1 mL, 0.1 mL lyophilized Hepatitis B virus (core antigen)
NCL-HBcAg-506 P
Clone 1044/341
1 mL lyophilized Hepatitis B virus (surface antigen)
NCL-HBsAg-2 F P (Enzyme)
Hepatitis B virus is one of an expanding list of hepatitis viruses. The
complete infective virion is a 42nm particle (Dane particle). The infective
virion consists of a core of double stranded DNA, a specific DNA
polymerase and structural proteins surrounded by an outer envelope,
Hepatitis B surface antigen (HBsAg). The nucleocapsid contains two
serologically distinct antigens; core antigen and ‘e' antigen. Core antigen is
localized predominantly within the nucleus of infected hepatocytes,
whereas ‘e' antigen is found in the cytoplasm of infected hepatocytes. A
significant proportion of carriers infected with the Hepatitis B virus may
develop persistent infection, chronic hepatitis of various types, cirrhosis and
possible primary hepatocellular carcinoma.
Product Specific Information
NCL-HBcAg-506 recognizes core antigen which is localized predominantly
within the nucleus. NCL-HBsAg-2 reacts with surface antigen.
Human liver, hepatitis B positive: immunohistochemical staining for hepatitis B core antigen
using NCL-HBcAg-506. Note intense nuclear staining of infected hepatocytes. Paraffin section.
Hepatitis C virus (NS3)
Clone MMM33
1 mL, 0.1 mL lyophilized NCL-HCV-NS3 F P (HIER)
Hepatitis C virus (HCV) is the leading cause of blood-borne and community
acquired non-A, non-B hepatitis. HCV infection has been estimated to affect
about 3 percent of the population worldwide. Higher prevalence occurs in
high-risk groups, which include individuals with a history of intravenous
drug abuse and those multiply transfused before the introduction of mass
screening of donated blood for viral antibodies. The virus persists in
approximately 80 percent of those infected. Twenty percent of individuals
with chronic infection progress to cirrhosis after an average of 20 years.
Hepatocellular carcinoma is a significant risk in these, occurring in around 3
percent annually. Virus antigen has been reported in the cytoplasm of
hepatocytes of infected individuals by immunohistochemistry although the
sensitivity of detection of antigen has varied from study to study.
Product Specific Information
NCL-HCV-NS3 is a monoclonal antibody raised against a recombinant NS3
protein.
Products in this catalog are subject to regulatory approval.
This catalog is not for use in the USA.